The company said it wants the postholder to ‘identify, influence and shape public health policy and the socio-economic and political environment to support vaccines' public affairs initiatives in the UK'.
Chiron Vaccines made headlines two years ago when production of its flu vaccine was suspended because of fears of bacterial contamination.
It has emerged that upon Novartis's acquisition of Chiron, Europe executive director of policy and public affairs Frances Luff stepped down. She is now acting as a freelance consultant on public policy.
